Understanding how FOXA1 is regulated in breast cancer
Official title: Posttranslational Regulation of FOXA1 in Breast Cancer
Funded at Comprehensive Cancer Center/ Univ/pr · NIH-10900643 · Data updated 2026-11-12
This study is looking at how a protein called FOXA1 affects breast cancer and why some tumors stop responding to hormone treatments, with the goal of finding new ways to help patients get better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Comprehensive Cancer Center/ Univ/pr NIH-funded |
| Lab location | 1 site (San Juan, United States) |
| Project start | September 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $365,705 |
| NIH project number | 5R01CA273444-04 |
| Project ID | NIH-10900643 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with breast cancer, particularly those whose tumors express estrogen receptor alpha and exhibit resistance to endocrine therapies.
✕Less likely to help
Patients with breast cancer who do not express estrogen receptor alpha or those with early-stage disease may not benefit from this research.
What this research studies
This research investigates the role of FOXA1, a key transcription factor, in breast cancer, particularly in relation to estrogen receptor alpha (ER) and resistance to endocrine therapies. The study aims to uncover how FOXA1 is regulated and how it contributes to cancer progression, especially in cases where tumors become resistant to treatment. By examining the interactions between the endocrine and immune systems, the research seeks to identify new mechanisms that could be targeted to improve treatment outcomes for patients. The approach includes analyzing chromatin accessibility and gene expression changes in response to inflammatory signals.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that overcome resistance to current breast cancer treatments.
How similar studies have gone: Other research has shown promising results in targeting transcription factors and their regulatory mechanisms in cancer treatment, indicating potential for success in this area.
Where this research is happening
-
Comprehensive Cancer Center/ Univ/pr
San Juan, United States Active
Researchers
- Principal investigator: Franco, Hector Luis — Comprehensive Cancer Center/ Univ/pr
- Study coordinator: Franco, Hector Luis
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.